Adiposity factors are not related to the presence of colorectal adenomas

Clinical and Experimental Gastroenterology

Volumn 4, Issue 1, 2011, Pages 257-261

  Chronis, Aris ^a   Thomopoulos, Konstantinos ^a   Sapountzis, Apostolos ^a   Triantos, Christos ^a   Kalafateli, Maria ^a   Kalofonos, Charalampos ^a   Nikolopoulou, Vassiliki ^a  

^a UNIVERSITY HOSPITAL OF PATRAS   (Greece)

Author keywords

Adiponectin; Adiposity; Colorectal adenoma; Polyp

Indexed keywords

ADIPONECTIN; C PEPTIDE; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN; INSULIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ADENOMATOUS POLYP; ADIPONECTIN BLOOD LEVEL; ADULT; ADVANCED CANCER; AGED; ARTICLE; BODY MASS; COLONOSCOPY; COLORECTAL ADENOMA; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; OBESITY; PROTEIN BLOOD LEVEL; WAIST CIRCUMFERENCE;

EID: 84856201590     PISSN: None     EISSN: 11787023     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Schoen RE, Tangen CM, Kuller LH, et al. Increased blood glucose and insulin, body size, and indent colorectal cancer. J Natl Cancer Inst. 1999;91(13):1147-1154.
2. MacInnis RJ, English DR, Haydon AM, Hopper JL, Gertig DM, Giles GG. Body size and composition and risk of rectal cancer (Australia). Cancer Causes Control. 2006;17(10):1291-1297.
3. Pischon T, Lahmann PH, Boeing H, et al. Body size and risk of colon and rectal cancer in the European Prospective Investigation Into Cancer and Nutrition (EPIC). J Natl Cancer Inst. 2006;98(13):920-931.
4. Tsugane S, Inoue M. Insulin resistance and cancer: epidemiological evidence. Cancer Sci. 2010;101(5):1073-1079.
5. Johnson KT, Harmsen WS, Limburg PJ, Carston MJ, Johnson CD. Visceral fat analysis at CT colonography. Acad Radiol. 2006;13(8):963-938.
6. Kang HW, Kim D, Kim HJ, et al. Visceral obesity and insulin resistance as risk factors for colorectal adenoma: a cross-sectional, case-control study. Am J Gastroenterol. 2010;105(1):178-187.
7. Morimoto LM, Newcomb PA, Ulrich CM, Bostick RM, Lais CJ, Potter JD. Risk factors for hyperplastic and adenomatous polyps: evidence for malignant potential? Cancer Epidemiol Biomarkers Prev. 2002;11(10 Pt 1):1012-1018.
8. Terry MB, Neugut AI, Bostick RM, et al. Risk factors for advanced colorectal adenomas: a pooled analysis. Cancer Epidemiol Biomarkers Prev. 2002;11(7):622-629.
9. Lieberman DA, Prindiville S, Weiss DG, Willett W; VA Cooperative Study Group 380. Risk factors for advanced colonic neoplasia and hyperplastic polyps in asymptomatic individuals. JAMA. 2003;290(22):2959-2967.
10. Bayerdörffer E, Mannes GA, Ochsenkühn T, Köpcke W, Wiebecke B, Paumgartner G. Increased risk of 'high-risk' colorectal adenomas in overweight men. Gastroenterology. 1993;104(1):137-144.
11. Stemmermann GN, Heilbrun LK, Nomura AM. Association of diet and other factors with adenomatous polyps of the large bowel: a prospective autopsy study. Am J Clin Nutr. 1988;47(2):312-317.
12. Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol. 2000;20(6):1595-1599.
13. Kumada M, Kihara S, Sumitsuji S, et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol. 2003;23(1):85-89.
14. Kondo H, Shimomura I, Matsukawa Y, et al. Association of adiponectin mutation with type 2 diabetes: a candidate gene for the insulin resistance syndrome. Diabetes. 2002;51(7):2325-2328.
15. Ouchi N, Kihara S, Arita Y, et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-pB signalling through a cAMPdependent pathway. Circulation. 2000;102(11):1296-1301.
16. Ouchi N, Kihara S, Funahashi T, et al. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation. 2003;107(5):671-674.
17. Engeli S, Feldpausch M, Gorzelniak K, et al. Association between adiponectin and mediators of inflammation in obese women. Diabetes. 2003;52(4):942-947.
18. Petridou E, Mantzoros C, Dessypris N, et al. Plasma adiponectin concentrations in relation to endometrial cancer: a case-control study in Greece. J Clin Endocrinol Metab. 2003;88(3):993-997.
19. Miyoshi Y, Funahashi T, Kihara S, et al. Association of serum adiponectin levels with breast cancer risk. Clin Cancer Res. 2003;9(15):5699-5704.
20. Wei EK, Giovannucci E, Fuchs CS, Willett WC, Mantzoros CS. Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. J Natl Cancer Inst. 2005;97(22):1688-1694.
21. Erarslan E, Turkay C, Koktener A, Koca C, Uz B, Bavbek N. Association of visceral fat accumulation and adiponectin levels with colorectal neoplasia. Dig Dis Sci. 2009;54(4):862-868.
22. Gonullu G, Kahraman H, Bedir A, Bektas A, Yücel I. Association between adiponectin, resistin, insulin resistance, and colorectal tumors. Int J Colorectal Dis. 2010;25(2):205-212.
23. Brakenhielm E, Veitonmäki N, Cao R, et al. Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci U S A. 2004;101(8):2476-2481.
24. Michalakis K, Williams CJ, Mitsiades N, et al. Serum adiponectin concentrations and tissue expression of adiponectin receptors are reduced in patients with prostate cancer: a case control study. Cancer Epidemiol Biomarkers Prev. 2007;16(2):308-313.
25. Fukumoto J, Otake T, Tajima O, et al. Adiponectin and colorectal adenomas: Self Defense Forces Health Study. Cancer Sci. 2008;99(4):781-786.
26. Nakajima TE, Yamada Y, Hamano T, et al. Adipocytokines as new promising markers of colorectal tumors: adiponectin for colorectal adenoma, and resistin and visfatin for colorectal cancer. Cancer Sci. 2010;101(5):1286-1291.
27. Yamaji T, Iwasaki M, Sasazuki S, Tsugane S. Interaction between adiponectin and leptin influences the risk of colorectal adenoma. Cancer Res. 2010;70(13):5430-5437.
28. Otake S, Takeda H, Suzuki Y, et al. Association of visceral fat accumulation and plasma adiponectin with colorectal adenoma: evidence for participation of insulin resistance. Clin Cancer Res. 2005;11(10):3642-3646.
29. Otake S, Takeda H, Fujishima S, et al. Decreased levels of plasma adiponectin associated with increased risk of colorectal cancer. World J Gastroenterol. 2010;16(10):1252-1257.
30. Kumor A, Daniel P, Pietruczuk M, Małecka-Panas E. Serum leptin, adiponectin, and resistin concentration in colorectal adenoma and carcinoma (CC) patients. Int J Colorectal Dis. 2009;24(3):275-281.
31. Fujisawa T, Endo H, Tomimoto A, et al. Adiponectin suppresses colorectal carcinogenesis under the high-fat diet condition. Gut. 2008;57(11):1531-1538.
32. Sedjo RL, Byers T, Levin TR, et al. Change in body size and the risk of colorectal adenomas. Cancer Epidemiol Biomarkers Prev. 2007;16(3):526-531.
33. Bobe G, Murphy G, Rogers CJ, et al. Serum adiponectin, leptin, C-peptide, homocysteine, and colorectal adenoma recurrence in the Polyp Prevention Trial. Cancer Epidemiol Biomarkers Prev. 2010;19(6):1441-1452.
34. Ishikawa M, Kitayama J, Kazama S, Hiramatsu T, Hatano K, Nagawa H. Plasma adiponectin and gastric cancer. Clin Cancer Res. 2005;11(2 Pt 1):466-472.